PMID- 11772460
OWN - NLM
STAT- MEDLINE
DCOM- 20020228
LR  - 20220410
IS  - 0168-3659 (Print)
IS  - 0168-3659 (Linking)
VI  - 78
IP  - 1-3
DP  - 2002 Jan 17
TI  - Enhanced bone formation by controlled growth factor delivery from chitosan-based 
      biomaterials.
PG  - 187-97
AB  - For the purpose of obtaining high bone forming efficacy, development of chitosan 
      was attempted as a tool useful as a scaffolding device. Porous chitosan matrices, 
      chitosan-poly(L-lactide) (PLLA) composite matrices and chitosan coated on PLLA 
      matrices were dealt with in this research. Porous chitosan matrix was fabricated 
      by freeze-drying and cross-linking aqueous chitosan solution. Porous chitosan 
      matrix combined with ceramics and constituents of extracellular matrices were 
      prepared and examined for their bone regenerative potential. Composite porous 
      matrix of chitosan-PLLA was prepared by mixing polylactide with chitosan and 
      freeze-drying. All chitosan based devices demonstrated improved bone forming 
      capacity by increasing mechanical stability and biocompatibility. Release of 
      platelet-derived growth factor-BB (PDGF-BB) from these matrices exerted 
      significant osteoinductive effect in addition to the high osteoconducting 
      capacity of the porous chitosan matrices. The hydrophobic surface of PLLA 
      matrices was modified by chitosan to enhance cell affinity and wettability. The 
      chitosan coated PLLA matrix induced increased osteoblast attachment as compared 
      with intact PLLA surface. Overall results in this study demonstrated the 
      usefulness of chitosan as drug releasing scaffolds and as modification tools for 
      currently used biomaterials to enhance tissue regeneration efficacy. These 
      results may expand the feasibility of combinative strategy of controlled local 
      drug delivery concept and tissue engineered bone formation in reconstructive 
      therapy in the field of periodontics, orthopedics and plastic surgery.
FAU - Lee, Jue-Yeon
AU  - Lee JY
AD  - Department of Pharmacy, College of Pharmacy, Ewha Womans University, 11-1 
      Daehyun-dong, Seodaemun-Ku, 120-750, Seoul, South Korea.
FAU - Nam, Sung-Heon
AU  - Nam SH
FAU - Im, Su-Yeon
AU  - Im SY
FAU - Park, Yoon-Jeong
AU  - Park YJ
FAU - Lee, Yong-Moo
AU  - Lee YM
FAU - Seol, Yang-Jo
AU  - Seol YJ
FAU - Chung, Chong-Pyoung
AU  - Chung CP
FAU - Lee, Seung-Jin
AU  - Lee SJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (Proto-Oncogene Proteins c-sis)
RN  - 1398-61-4 (Chitin)
RN  - 1B56C968OA (Becaplermin)
RN  - 9012-76-4 (Chitosan)
SB  - IM
MH  - Animals
MH  - Becaplermin
MH  - *Bone Regeneration
MH  - Cell Division
MH  - Cells, Cultured
MH  - Chitin/*administration & dosage/analogs & derivatives
MH  - Chitosan
MH  - Osteoblasts/physiology
MH  - Osteogenesis
MH  - Platelet-Derived Growth Factor/*administration & dosage
MH  - Proto-Oncogene Proteins c-sis
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Tissue Engineering
EDAT- 2002/01/05 10:00
MHDA- 2002/03/01 10:01
CRDT- 2002/01/05 10:00
PHST- 2002/01/05 10:00 [pubmed]
PHST- 2002/03/01 10:01 [medline]
PHST- 2002/01/05 10:00 [entrez]
AID - S0168365901004989 [pii]
AID - 10.1016/s0168-3659(01)00498-9 [doi]
PST - ppublish
SO  - J Control Release. 2002 Jan 17;78(1-3):187-97. doi: 
      10.1016/s0168-3659(01)00498-9.